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OBJECTIVE: To understand the role of apoptosis
through Fas/Fas ligand (FasL) interaction in the
pathogenesis of silicosis, we examined the expres-
sion of Fas antigen, FasL and apoptosis in bronch-
oalveolar lavage fluid lymphocytes obtained from
patients with silicosis.
Materials and methods: Ten patients with silicosis,
and 10 healthy controls were studied. Non-adherent
cells were separated and analysed by cytometry for
the expression of Fas antigen, FasL, and the co-
expression of Fas/FasL. By double staining, we
studied the FasL expression on CD4, CD8, CD56 and
CD45RO-positive cells. DNA fragmentation was in-
vestigated by the terminal deoxy(d) UTP nick end
labelling (TUNEL) method.
Results: We have found Fas and FasL expression in
silicosis patients to be significantly higher than those
in healthy controls. Interestingly, 6 
/18% of lympho-
cytes from silicosis patients co-expressed Fas and
FasL. In silicosis patients, FasL was highly expressed
on CD4
, CD56
 and CD45RO
 bronchoalveolar
lavage cells. Fas antigen expressing cells showed
DNA fragmentation characteristic for apoptosis.
Conclusion: FasL was significantly expressed on
cytotoxic effector and memory cells. The Fas/FasL
system is implicated in the inflammatory process
observed in silicosis patients.
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Introduction
Silicosis is characterized by pulmonary lesions and
various immunological abnormalities such as hyper-
gammaglobulinaemia and the appearance of auto-
antibodies that are in some cases associated with
clinical autoimmune manifestations.
1,2 However, the
mechanisms involved in the occurrence of immuno-
dysfunction induced by silica compounds have not
yet been determined. Silica compounds such as
chrysotile, crocidolite anthophyllite, act as super-
antigens to activate human T cells polyclonally in
vitro.
3 Silica compounds have been found to induce
an increase in intracellular calcium concentrations,
4,5
enhancement of interleukin (IL)-2 secretion and
activation of particular T-cell receptor Vb5.3 in human
peripheral blood T cells.
6,7
It has been reported that serum levels of the
soluble Fas (sFas) molecule were elevated in silicosis
patients with no clinical symptoms of autoimmune
diseases such as sclerotic skin, Raynaud’s phenom-
enon, or arthralgia.
8 The sFas message derived from
peripheral blood mononuclear cells was dominantly
expressed in these patients.
9 Based on these investi-
gations, dysregulation of the Fas-mediated apoptotic
pathway may play an important role in the pathogen-
esis of the immunological abnormalities found in
silicosis. In addition, it has been reported that
silicone-containing macrophages prevent activation-
induced cell death in murine lymphocytes.
10 These
results have led us to consider that it may be difficult
for the T lymphocytes in patients with silicosis to
proceed into apoptosis mediated by the Fas-related
pathway. Moreover, based on previous results, which
demonstrated that silica compounds act as super-
antigens against human T cells,
6 these T cells might
include self-recognizing clones. On the contrary,
Smalley et al.
11 reported that the T-cell response to
silicon dioxide is monocyte dependent and not a
superantigen.
Recent studies have demonstrated the presence of
Fas and FasL gene mutations in the lpr and gld mice,
which are used as a model of autoimmune diseases,
resulting in defects in the apoptotic process.
12,13
Recent results demonstrated a spontaneous occur-
rence of apoptosis in the inflammatory sites of
rheumatoid arthritis in vivo and demonstrated that
this process was mediated by Fas antigen in
vitro.
14 16 Therefore, it is suggested that the Fas/
FasL system may be involved in the pathogenesis of
silicosis. In lung silicosis, mechanisms leading to
lymphocyte activation are still poorly understood,
and no data were reported about investigations in
human bronchoalveolar lavage (BAL) of silicosis
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209patients, which constitute an interesting way to
explore in vivo the apoptosis pathway in silicosis.
We studied the expression of Fas antigen and FasL
in BAL fluid lymphocytes from silicosis patients. To
clarify whether apoptosis occurred in the Fas antigen-
positive cells of silicosis, we also examined the
relationship between Fas/FasL antigen expression
and CD4, CD8, CD56 and CD45RO BAL lymphocytes.
Our results demonstrated that FasL was expressed on
BAL-CD45RO
  T cells and CD56
  cells. Our findings
suggest that the Fas/FasL system may represent one
of the mechanisms of apoptosis in BAL, and that it
may be the consequence of silica dust activation in
the lung.
Patients and methods
Patients and sera
Ten patients with silicosis were studied (seven
smokers and three non-smoker men; 38 /69 years;
mean age, 54 years; average age, 489 /7 years) with
no clinical symptoms of autoimmune diseases such as
sclerotic skin, or arthralgia. Silicosis was assessed
according to the International Labor Office criteria:
patients experienced a heavy and prolonged occupa-
tional exposure to silica dust, and showed roentgen-
ological and functional signs of silicosis. Ten healthy
volunteers (all men; four smokers and six non-
smokers; average age, 259 /2 years) acted as controls.
Informed consent had been obtained from patients
and controls. The study was approved by the local
Ethics Committee.
BAL analysis
The BAL procedure was performed mainly as de-
scribed elsewhere.
17 The cellular fraction was pre-
dominantly mononuclear ( /90%). BAL fluids were
filtered through a single layer of sterile gauze (Sincab,
Malmo, Sweden). After centrifugation (500 rpm for 10
min), the cell pellets were washed twice in phos-
phate-buffered saline. Alveolar macrophages were
separated from lymphocytes by adherence to plastic
(Costar, Cambridge, MA, USA) for 2 h at 378C and 5%
CO2. Cell differential counts were determined by
Wright /Giemsa staining. The results of BAL analysis
of the aliquots are presented in Table 1. Calculations
were made in duplicate and expressed as the mean9 /
standard error of the mean. Cells were  /94% viable
as determined by the trypan blue exclusion test.
The mean CD4/CD8 ratio in silicosis patients was
(1.39 /0.9; range, 1.2 /1.8) significantly different com-
pared with in healthy controls (1.99 /0.8; range, 1.6 /
2.3, pB/0.05). Significant differences in the total cell
count were observed between silicosis patients and
healthy controls (Table 1).
Lymphocytes were separated into CD4
  and
CD8
  subsets by positive selection using coated
magnetic beads (Dynabeads; Dynal, Oslo, Norway)
as reported elswere.
18 Briefly, cells were incubated
with magnetic beads coated with an anti-CD4 mono-
clonal antibody (mAb) at 48C for 1 h with rocking in 1
ml of RPMI 1640 medium plus 0.01% human serum
albumin (Bayer Corporation, Marseille, France).
CD4
  cells were collected using a magnet, and the
remaining cells were collected and improved again
with an anti-CD8
  mAb. To improve purity, the
magnetic beads and attached cells were gently
resuspended in 3 ml of RPMI 1640 medium plus
0.01% human serum albumin, and CD4
  or CD8
 
cells were again collected with a magnet. The purity
of the preparations obtained was for CD4
  cells
(CD4
   /94%, CD8
  B/6%) and for CD8
  cells
(CD8
   /95%, CD4
  B/5%).
Immunohistochemical analysis
The following mAbs were used: anti-CD3, anti-CD4,
anti-CD8, anti-CD56 and anti-CD45RO (Sigma, Al-
drich, Germany). Cytospins were prepared by adding
75 ml of cell suspension into Shandon cytocentrifuge-
3 cups (Shandon Instruments, London, UK) and spun
for 8 min at 500 rpm. We performed immunohisto-
chemical double staining with each of the antibodies
on the blocked cytospin slides. Cells preparations
were incubated with the mAbs anti-Fas (UB2) and
anti-FasL (NOK2). For anti-Fas detection an immu-
noperoxidase procedure was performed using the
ABC kit (Vector Laboratories, Marseille, France), and
anti-FasL was visualized by direct labelling with CY3
(Biological Detection Systems, Inc., Pittsburgh, PA,
USA) for double staining as described in the follow-
ing. Negative control studies were performed for
each experiment by isotype-matched control mAb.
Following the first immunohistochemical staining,
we performed immunohistochemical double staining
with each of the following antibodies: anti-Fas, anti-
FasL, anti-CD3, anti-CD4, anti-CD8, anti-CD56 and
anti-CD45RO (Dako, Marseille, France). After dupli-
cate washing with phosphate-buffered saline, the
slides were incubated with fluorescein isothiocya-
Table 1. Characteristics of BAL analysis in silicosis patients
and in healthy controls
Silicosis patients Healthy controls
Recovery (%) 74.89 /7.3 72.79 /2.8
Total cell 9.4 10
6 $ 12.6 10
6
Macrophage (%) 89.69 /9.4 87.59 /2.3
Lymphocyte (%) 9.29 /2.7 11.79 /0.6
Neutrophil (%) 1.69 /0.7 0.99 /0.2
Eosinophil (%) 0.69 /0.4 0.79 /0.3
CD4/CD8 ratio 1.39 /0.9
$ 1.99 /0.8
Data expressed as mean9 /standard eror of the mean.
$ pB/0.05 compared with healthy controls.
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(Dako) or visualized by the APAAP system (Dako).
Certain patients were also studied by cytofluoro-
metric analysis. The lymphocyte fraction was gated
and the percentage of Fas-positive cells or fluores-
cence intensity was studied. Cytofluorometric analy-
sis, counting 1000 cells/sample, were performed on a
fluorescence activated cell analyser (FACScan; Becton
Dickinson) as we have reported elsewhere.
19 Positive
cells were determined by setting a threshold with
reference to the relevant negative control.
Detection of apoptosis by DNA nick end
labelling (TUNEL)
Terminal deoxy(d) UTP nick end labelling (TUNEL)
was performed as described according to the method
of Gavrieli et al.,
20 with few modifications. Non-
adherent cells were adjusted to 1.2 /10
6 cells/ml.
Briefly, cell preparations were immersed in terminal
deoxynucleotidyl transferase (TDT) buffer (30 mM of
Trizma base, pH 7.2, 140 mM of sodium cacodylate,
1.0 mM of cobalt chloride). TDT (0.3 units/ml) and
biotinylated dUTP or digoxygenin-dUTP in TDT
buffer were then added to the samples. The reaction
was terminated by placing the slides in the TB buffer
(300 mM of sodium chloride, 30 mM of sodium
citrate), and samples were visualized with the ABC kit
(Vector Laboratories). Negative control studies were
performed by omitting the TDT.
Reverse transcription-polymerase chain reaction
Southern blot analysis.
We prepared total RNA (6 /12 mg) using 10
7 BAL
lymphocytes obtained from four silicosis patients. In
addition, CD4
  and CD8
  cells were prepared using
the bead separation method described earlier. cDNA
synthesis and polymerase chain reaction (PCR) were
performed. Cells were stimulated with 10 ng/ml of
phytohaemagglutinin P (Difco Laboratories, Detroit,
MI, USA). Briefly, first-strand cDNAs were synthe-
sized in a 20 ml reaction mixture containing oligo(dT)
primer using 1.0 mg of total RNA. PCR was performed
with primers specific for FasL (5?-primer,
5?-CGCCACCACTGCCTCCACTA-3?;3 ?-primer, 5?-
CTTCCCCTCCATCATCACC A-3?) or primers for b-
actin (5?-primer, 5?-TACATGGCTGGGGTG21TGGAA-
3?;3 ?-primer, 5?-AAGAGAGGCATCCTC-ACCCT-3?)
described elsewhere.
21 Denaturing was performed
at 948C for 90 sec, annealing at 608C for 90 sec, and
extension at 728C for 60 sec, for 30 cycles on a DNA
thermal cycler (Perkin-Elmer, Norwalk, CT, USA). In
the next step, 10% of the PCR products (FasL, 492
base pairs; b-actin, 246 base pairs) was subjected to
2% agarose gel electrophoresis and hybridized with
digoxygenin-labelled PCR product probe encoding
FasL or b-actin genes as described elsewhere.
22
Statistical analysis
Data are expressed as the mean9 /standard error of
the mean. Statistical significance was calculated using
the Mann /Whitney U-test for non-parametric data.
pB/0.05 denoted the presence of a statistical sig-
nificant difference.
Results
Fas antigen expression in BAL fluid cells
We examined the expression of Fas antigen in BAL
lymphocytes from silicosis patients and healthy con-
trols (Fig. 1). The expression of CD3
  cells was  /
85% both in silicosis patients and in healthy controls.
Staining with anti-Fas mAb showed that 21 /37% of
cells were positive for Fas antigen in BAL lympho-
cytes from silicosis patients (mean, 29.6%). In healthy
control BAL lymphocytes, only 6 /14% of cells
expressed Fas antigen (mean, 9.4%).
FasL expression in BAL fluid lymphocytes.
In the next step, we examined the expression of FasL
in BAL fluid lymphocytes (Fig. 1). The expression of
FasL was analysed using anti-FasL mAb. Thirty-three
per cent to 47% (mean, 39.1%) of positively stained
cells with anti-FasL mAb were detected in all BAL
lymphocytes from silicosis patients. In contrast, there
were very few FasL-positive cells in the BAL fluid
lymphocytes from healthy controls (B/10%; mean,
5.7%).
Double staining with anti-Fas and anti-FasL mAbs
(Fig. 1) also revealed that FasL-positive lymphocytes
were occasionally observed in Fas-positive cells from
healthy controls (2 /5%; mean, 4.3%). Interestingly,
6 /18% of lymphocytes co-expressed both Fas and
FasL in silicosis patients (mean, 13.5%).
Apoptosis in BAL: lymphocytes and relationship
with Fas-positive cells
Apoptosis in silicosis patient BAL was investigated
using the TUNEL method (Table 2). The number of
apoptotic cells in silicosis patients was significantly
higher (23.29 /3.9%) than that in healthy controls
(4.89 /1.7%, pB/0.05). DNA fragmentation was seen
in 13 /27% (mean, 19.1%) of BAL Fas-positive cells. In
contrast, 3 /7% of Fas-positive cells in healthy con-
trols were positive for TUNEL.
FasL expression on T cells and natural killer cells
in BAL
Double staining was performed to determine the type
of cells expressing FasL in BAL fluid. Expression of
Fas antigen and FasL in silicosis
Mediators of Inflammation Vol 12  2003 211FasL in silicosis patients was detected in 13 /26% of
CD3
  cells (mean, 19.3% versus 4.3% in healthy
controls, pB/0.005), in 12 /18% of CD56
  cells
(mean, 16.4% versus 1.5% in healthy controls, pB/
0.005), and in 2 /6% of CD45RO
  cells (mean, 4.2%
versus 1.7 in healthy controls, p B/0.005).
To confirm the expression of FasL in CD4
  or
CD8
  T cells in the BAL by positive selection using
antibody-coated magnetic beads, reverse transcrip-
tion-PCR Southern blot analysis was performed using
CD4
  or CD8
  cells separated from the BAL fluid
lymphocytes. Both CD4
  and CD8
  cells from
silicosis patients appeared to express FasL mRNA
(Fig. 2).
Discussion
The major finding of the present study was the
increased expression of Fas and FasL-positive cells
in silicosis BAL. Inflammatory CD4
 ,C D 8
 , CD56
 
and CD45RO
  cells in BAL from silicosis patients
preferentially express FasL compared with BAL
lymphocytes from healthy controls. During experi-
mental silicosis, exposed inbred strains of mice to an
aerosol of cristobalite silica showed accumulation of
activated lymphocytes in alveolar spaces over months
after exposure.
23 CD4
 , CD8
 , T-cell receptor gd
 
and CD56
  lung cells produced increased levels of
interferon-g,
23,24 suggesting a Th1-like response. The
authors hypothesized that there is a reiterative
FIG. 1. Expression of Fas and FasL on BAL lymphocytes from silicosis patients and healthy controls (H.C.).
Table 2. The percentages of apoptosis in BAL mononuclear
cells and Fas antigen expression
Patients Fas (%) Apoptosis (%) DNA fragmentation
in Fas
  cells
12 2 2 5 1 8
22 7 1 4 1 3
33 7 2 3 1 9
43 0 2 5 2 1
53 5 1 9 1 6
62 8 3 2 2 3
72 3 2 7 2 0
83 4 3 0 2 7
92 9 1 3 1 2
10 31 24 22
FIG. 2. FasL expression on CD4 and CD8 T cells. Lympho-
cytes from BAL were separated into CD4
  and CD8
  subsets
by positive selection using antibody-coated magnetic beads.
The expression of FasL (A) and b-actin (B) on phytohaemag-
glutinin (PHA)-stimulated BAL lymphocytes from silicosis
patients (lane 1), PHA-stimulated BAL lymphocytes from
healthy controls (lane 2), and separated CD4
  (lane 3) and
CD8
  (lane 4) T cells were examined by reverse transcrip-
tion-PCR and followed Southern blot analysis as described in
Materials and methods. bp, base pairs.
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produce cytokines such as IL-12 and IL-18, which
attract and activate lymphocytes.
3 The Th1/Th2 im-
balance is favourable to apoptosis dysregulation.
Previous studies revealed high serum sFas levels in
silicosis patients without any clinical symptoms of
autoimmune disease.
25 Fas belongs to the TNF
receptor family, and alternative mRNA splicing pro-
duces sFas molecules.
26 In our silicosis group, sFas
levels were increased in BAL fluid (data not shown).
sFas molecules can protect cells from apoptosis,
inhibiting Fas/FasL interactions. Dysregulation of
the Fas gene may play an important role in the
pathogenesis of the immunological abnormalities
found in silicosis patients.
27
The Fas/FasL system have been involved in the
cell-mediated cytotoxicity.
28 In the present study, we
suggested the possibility that Fas/FasL interaction in
lung silicosis is another pathway of cytotoxicity, since
both Fas antigen and FasL were expressed in the lung
lymphocytes. FasL expression was observed in CD56-
positive cells. On the contrary, Fas and FasL expres-
sion were co-expressed in lung lymphocytes. FasL
tend to be highly expressed in silicosis lymphocytes,
compared with healthy controls. The dysregulation in
Fas/FasL expression is specific to inflammatory sites.
Patients with rheumatoid arthritis expressed high
level of Fas-positive cells in their synovial tissue.
29
Fas-positive cultured synovial cells from rheumatoid
arthritis patients undergo apoptosis with anti-Fas
mAb in vitro.
30
The expression of FasL by CD4
  and CD8
  T cells
represented a way of cytotoxicity via the Fas/FasL
interactions in silicosis patients. CD4
  and CD8
  T
cells, proliferating in silicosis lung inflammatory sites,
could be accumulated by dust silica as antigen-driven
mechanisms. FasL was highly expressed on
CD45RO
  cells in silicosis patients. The expression
of CD45RO
  cells indicate a proportion of T cells
with a memory phenotype
31 expressing the protein
kinase C activation,
32 and may explain the greater
amount of IL-2 and interferon-g secretion by CD4
 
cells.
33
In silicosis patients we think that CD45RO
  cells
acted as killer effector cells. In our patients, a
considerable proportion of CD4
  T cells in BAL are
already committed, without other antigenic stimula-
tion, to differentiate to Th1-like cells. It has been
reported that the proliferation of CD45RO
  T cells is
accompanied by a striking increase in apoptotic
activity.
34 Such observation implies that primed T
cells are eliminated at a high rate by apoptosis. The
expression of CD45RO molecule was the result of an
antigen stimulation or its equivalent that down-
regulates the CD45RA molecule.
35 It has been re-
ported that CD45RO and other similar epitopes are
also expressed on T cells undergoing apoptosis
following activation.
36
An important percentage (19%) of Fas-positive BAL
cells showed DNA fragmentation detected by TUNEL.
Furthermore, FasL-positive lymphocytes were ob-
served around Fas-positive BAL cells in silicosis
patients. These data suggest the possibility that
apoptosis may occur through the interaction of Fas/
FasL. Interestingly, 13.5% of BAL lymphocytes co-
expressed both Fas and FasL, suggesting that Fas/
FasL interactions may function in paracrine and
autocrine mechanisms. This may be relevant to the
abnormal immune responses in the inflammatory
lung cells. However, our results did not exclude other
apoptotic pathways, different from the Fas/FasL
system.
In summary, the present data revealed that a
number of activated T cells and natural killer cells
infiltrating the BAL fluid from silicosis patients were
activated in vivo. This suggests that the mechanism of
elimination of certain Fas-positive cells involves
apoptosis mediated by Fas/FasL interaction. Our
study may help to expand our understanding of the
inflammation process in silicosis.
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